Semaglutide (Wegovy) for weight loss

Med Lett Drugs Ther. 2021 Jul 12;63(1628):106-108.
No abstract available

Keywords: Qsymia; Saxenda; Wegovy; adverse effects; dosage; drug interactions; efficacy; lactation; liraglutide; phentermine; pregnancy; safety; semaglutide; topiramate; type 2 diabetes; weight loss.

Publication types

  • Review

MeSH terms

  • Clinical Trials as Topic / methods
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / epidemiology
  • Glucagon-Like Peptide 1 / agonists*
  • Glucagon-Like Peptide 1 / physiology
  • Glucagon-Like Peptides / administration & dosage*
  • Glucagon-Like Peptides / adverse effects
  • Humans
  • Injections, Subcutaneous
  • Nausea / chemically induced
  • Weight Loss / drug effects*
  • Weight Loss / physiology

Substances

  • semaglutide
  • Glucagon-Like Peptides
  • Glucagon-Like Peptide 1